stoxline Quote Chart Rank Option Currency Glossary
  
Lisata Therapeutics, Inc. (LSTA)
2.7  0.03 (1.12%)    04-19 16:00
Open: 2.75
High: 2.87
Volume: 1,829
  
Pre. Close: 2.67
Low: 2.67
Market Cap: 22(M)
Technical analysis
2024-04-19 5:10:46 PM
Short term     
Mid term     
Targets 6-month :  3.64 1-year :  3.97
Resists First :  3.12 Second :  3.4
Pivot price 2.95
Supports First :  2.67 Second :  2.22
MAs MA(5) :  2.79 MA(20) :  3.01
MA(100) :  2.88 MA(250) :  2.91
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  17.1 D(3) :  18.7
RSI RSI(14): 37.1
52-week High :  4.53 Low :  1.95
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LSTA ] has closed below the lower bollinger band by 0.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.88 - 2.89 2.89 - 2.9
Low: 2.63 - 2.65 2.65 - 2.67
Close: 2.67 - 2.7 2.7 - 2.72
Company Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Headline News

Sat, 13 Apr 2024
LSTA Stock Quote Price and Forecast - CNN

Wed, 10 Apr 2024
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma - Yahoo Finance

Wed, 03 Apr 2024
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events - GlobeNewswire

Fri, 22 Mar 2024
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma - Yahoo Finance

Thu, 21 Mar 2024
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of ... - GlobeNewswire

Thu, 29 Feb 2024
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 8 (M)
Shares Float 7 (M)
Held by Insiders 19 (%)
Held by Institutions 8.9 (%)
Shares Short 17 (K)
Shares Short P.Month 8 (K)
Stock Financials
EPS -2.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.9
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25.2 %
Return on Equity (ttm) -36.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.08
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -1.05
PEG Ratio -0.1
Price to Book value 0.45
Price to Sales 0
Price to Cash Flow -1.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android